Drug Trial Radar · NCT07570823
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
101
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Nov 2027
Study completion Apr 2029
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
Interventions
SCTB35 injectionDrug
SCTB35 will be subcutaneously administered at a dose as specified
RituxumabDrug
Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
GemcitabineDrug
Participants will receive IV gemcitabine administration for up to 8 cycles.
OxaliplatinDrug
Participants will receive IV oxaliplatin administration for up to 8 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Up to approximately 3 years
- Progression free survival (PFS)Time frame: Up to approximately 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.